Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers

Summary

The purpose of this study is to determine whether SYL1001 is safe for the prevention and treatment of ocular pain and dry eye syndrome.

Timeline

Start

2011-07

Primary completion

2011-11

Completion

2012-06

Outcome

Met primary endpoint

paper These trials achieved their primary endpoints of identifying the most effective dose of SYL1001 (1.125%). PMID 27893109 ↗

Publications

• Benitez-Del-Castillo JM, Moreno-Montanes J, Jimenez-Alfaro I, Munoz-Negrete FJ, Turman K, Palumaa K, Sadaba B, Gonzalez MV, Ruz V, Vargas B, Paneda C, Martinez T, Bleau AM, Jimenez AI. Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease. Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6447-6454. doi: 10.1167/iovs.16-20303.

Drugs

Indications